nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Additional Neurology Topics"

 

Assessing Knowledge About Traumatic Brain Injury Within Intimate Partner Violence Survivor Providers
December 4, 2019   

Traumatic brain injury, as a result of intimate partner violence, has serious negative mental and physical health consequences, yet there is still a gap in understanding the impact of intimate partner violence on head trauma. In a recent 2-phase study...
 Continue reading (Members only)
New Medication Approved for Migraine
October 29, 2019   

The US Food and Drug Administration (FDA) has approved lasmiditan for the acute treatment of migraine in adults...
 Continue reading (Members only)
Degree of Serotonin Reuptake Inhibition and Risk of Ischemic Stroke
September 3, 2019   

Untreated depression has been reported to be associated with cardiovascular disease, thus patients with increased risk for ischemia have been prescribed antidepressants. Previous research also suggests that strong inhibitors may reduce the risk of arterial ischemic activity, however...
 Continue reading (Members only)
Childhood Maltreatment and Adult Amygdala Function: Timing Matters
August 16, 2019   

Abnormal patterns of hyperactive and hypoactive amygdala responses have been associated with inappropriate social behaviors. Childhood maltreatment is often...
 Continue reading
Vascular Disease is a Major Cause of Mortality Following Inpatient Psychiatric Discharge
August 13, 2019   

In a recent meta-analysis, researchers looked at short- and long-term causes of mortality after inpatient psychiatric discharge. In the short-term period following discharge, mortality rates due to unnatural causes were equivalent to...
 Continue reading
Music Hath Charms to Soothe Patients with Dementia
March 19, 2019   

In patients with dementia, neuropsychiatric symptoms (including agitation, anxiety, apathy, and depression) are often the most troubling to both patients and caregivers and may drive earlier institutionalization. With no available disease-modifying treatments available for Alzheimer's disease, clinicians and caregivers rely...
 Continue reading (Members only)
Increased Risk of Basal Ganglia Disorders in Patients with a History of ADHD?
October 1, 2018   

A recent meta-analysis examined whether attention deficit hyperactivity disorder (ADHD), or treatments for the disorder alter the risk of diseases associated with the basal ganglia and cerebellum, including Parkinson’s disease...
 Continue reading
FDA Finds No Unexpected Safety Risk With Pimavanserin
September 24, 2018   

The Food and Drug Administration (FDA) recently completed an extensive review of all postmarking reports of serious adverse events (SAEs) and deaths linked to the use of Nuplazid (pimavanserin)...
 Continue reading
FDA Approves First Cannabis-Derived Medication
July 3, 2018   

The US Food and Drug Administration (FDA) has approved the first cannabis-based medicine to treat drug resistant childhood epilepsies...
 Continue reading
A Novel Preventive Treatment for Migraine
May 18, 2018   

The first treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks has been FDA-approved...
 Continue reading (Members only)
12345
Top of Page